Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

COURT: N.D. Cal. TRACK DOCKET: No. 3:24-cv-07786 (Bloomberg Law subscription) Pfizer Inc. and its subsidiary Global Blood Therapeutics Inc. should have known that their now-recalled treatment for ...

Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...

In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Fulcrum Therapeutics (FULC – Research Report), ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...